![Rick Schnellman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rick Schnellman
Fondateur chez Rediscovery Life Sciences LLC
Postes actifs de Rick Schnellman
Sociétés | Poste | Début | Fin |
---|---|---|---|
Rediscovery Life Sciences AKI LLC
![]() Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC. | Directeur/Membre du Conseil | - | - |
Directeur Technique/Scientifique/R&D | - | - | |
Rediscovery Life Sciences LLC
![]() Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC. | Directeur/Membre du Conseil | - | - |
Directeur Technique/Scientifique/R&D | - | - | |
Fondateur | - | - | |
Mitochem Therapeutics, Inc.
![]() Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Rick Schnellman
Statistiques
Internationale
Etats-Unis | 4 |
Opérationnelle
Director/Board Member | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Founder | 1 |
Sectorielle
Health Technology | 3 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Rediscovery Life Sciences AKI LLC
![]() Rediscovery Life Sciences AKI LLC Medical/Nursing ServicesHealth Services Rediscovery Life Sciences AKI LLC engages in the development of treatments with less risk through drug repurposing. The company is headquartered in Charleston, SC. | Health Services |
Rediscovery Life Sciences LLC
![]() Rediscovery Life Sciences LLC BiotechnologyHealth Technology Rediscovery Life Sciences LLC operates as a clinical-stage biotechnology company that focuses to develop suramin in acute kidney injury. The company was founded by Rick Schnellman and is headquartered in Charleston, SC. | Health Technology |
Mitochem Therapeutics, Inc.
![]() Mitochem Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Mitochem Therapeutics, Inc. is a privately held company based in Charleston, SC that develops therapies for diseases involving mitochondrial dysfunction. Mitochem Therapeutics has a proprietary library of mitochondrial protective compounds, and early proof of concept in numerous in vivo models for retinitis pigmentosa (RP) and age-related macular degeneration (AMD). The lead compound MC16 is a first-in-class small molecule that up-regulates pro-survival and anti-oxidant pathways. In 2021, the Food and Drug Administration (FDA) granted orphan drug designation status to MC16 for the treatment of RP. The company is pursuing partnerships to develop non-ophthalmic indications such as Parkinson's, Alzheimer's, ALS, muscular dystrophies, diabetes, ischemias, and kidney diseases. The company was founded by Bärbel Rohrer and Craig C. Beeson to develop a new approach to treating neurodegeneration and aging diseases by protecting mitochondrial homeostasis. The CEO is Michael Voevodsky. | Health Technology |
- Bourse
- Insiders
- Rick Schnellman
- Expérience